Breakthrough Designation for Medtronic's Sphere-9 Catheter Marks Major Advance in Electrophysiology

Source: Medical Device Business Review

On April 25, 2026, Medtronic announced,Its Sphere-9 catheter received FDA Breakthrough Device Designation, with indications targeting the treatment of ventricular tachycardia.

Source: PR Newswire

Sphere-9 is one of the core catheters of Affera's mapping and ablation platform. This catheter features a nitinol cage structure with a tip grid diameter of 9 millimeters, capable of simultaneously delivering radiofrequency energy and pulsed field energy. Previously, it has been approved for use in certain arrhythmia indications in the United States, Europe, Australia, and Japan, but has not yet been approved for ventricular tachycardia in any region.

Sphere-9 Mapping and Ablation Catheter

Ventricular tachycardia is a significant trigger of sudden cardiac death. The currently available interventional ablation tools still present a clinical gap that has yet to be fully addressed, as the balance between safety, operational efficiency, and long-term outcomes remains unresolved.

FDA Breakthrough Device Designation is typically granted to products that demonstrate a clinically meaningful potential advantage in treating serious diseases. This designation means that Sphere-9 has gained an accelerated pathway into the ventricular tachycardia market.Mechanism.(Breakthrough Device Designation corresponds to earlier communication and a faster review pathway during the product evaluation process.)

During the same period, Medtronic announced the early feasibility study data targeting post-myocardial infarction ventricular tachycardia patients. Six months after the ablation, 65% of the patients did not experience a recurrence of ventricular tachycardia. The study, participated in by researchers such as Dr. Reddy from the Mount Sinai Health System in New York, was described as "encouraging." Medtronic stated that it would advance this research to the IDE trial phase and expand the patient inclusion criteria.

Sphere-9 Receives Breakthrough Designation for Ventricular Tachycardia, Not an Isolated Product Milestone.

At the same annual meeting, Medtronic also presented the European subgroup analysis of another catheter, Sphere-360, under the Affera platform, as well as the news of the first patient enrolled in the Conquer-AF study for recurrent atrial fibrillation using Sphere-9.

The Sphere-360 catheter can expand to 34 millimeters, performing single-shot pulmonary vein isolation ablation without the need for catheter rotation. This analysis shows that in patients with coexisting left pulmonary veins, lesion durability reached 100%, consistent with the previously reported 98% durability per vein.

Two catheter sizes, one "small" and one "large",Sphere-9 is more precise, manually operated, pursuing flexible targeting; Sphere-360 is more "comprehensive," single coverage, pursuing reduced operation time.Two technical forms are placed on the same mapping and ablation platform, targeting different clinical scenarios.

This reflects the embodiment of a platform-based strategy. In August 2022, Medtronic acquired Affera, Inc. for $1 billion, integrating this platform into its electrophysiology division. Subsequently, the PulseSelect pulsed field ablation system received approval in December 2023, becoming the first system of its kind to gain FDA approval for atrial fibrillation. Today, Sphere-9 has established a commercial foundation in the atrial fibrillation space and is now expanding into the ventricular tachycardia field.TimeSphere-360Received CE Mark Certification in January 2026, Initiated the first cohort of IDE study in the United States, CoThe nquer-AF study also began to enroll recurrent patients who had previously undergone ablation surgery.

The timeline of these actions shows that,Medtronic is building a multi-catheter electrophysiology ablation matrix along the pathways of atrial fibrillation consolidation therapy, initial atrial fibrillation treatment, and ventricular tachycardia breakthrough attempts.

The progress of a product for one indication provides cash flow and accumulates user habits for another indication; the clinical data of a catheter inversely validates the energy output principle of the entire platform. Around the same platform, multiple indications and procedural pathways are being advanced in parallel.